CHDR Annual Report 2022
Scientific output

Our publications in 2022

  • Aulin LBS, Kleijburg A, Moerland M, et al. Characterizing the kinetics of presepsin and associated inflammatory biomarkers in human endotoxemia. Inflamm Res. 2022; 71(9):999-1001.
  • Baakman AC, Gavan C, van Doeselaar L, et al. Acute response to cholinergic challenge predicts long-term response to galantamine treatment in patients with Alzheimer's disease. Br J Clin Pharmacol. 2022; 88(6):2814-2829.
  • Bakkum MJ, Loobeek BJ, Richir MC, et al. Teaching resources for the European Open Platform for Prescribing Education - a nominal group technique study. NPJ Sci Learn. 2022; 7(1):23.
  • Bakkum MJ, Verdonk P, Thomas EG, et al. A Clinical Pharmacology and Therapeutics Teacher's Guide to Race-Based Medicine, Inclusivity, and Diversity. Clin Pharmacol Ther. Published online 2022.
  • Balak DMW, Rissmann R. Anti-interleukin-17A for pityriasis rubra pilaris: catching the psoriasis biologic wave. Br J Dermatol. 2022; 187(5):633-634.
  • Berfelo T, Doll RJ, Krabbenbos IP, et al. Observing Altered Nociceptive Detection Thresholds in Patients With Persistent Spinal Pain Syndrome Type 2 With a Dorsal Root Ganglion Stimulator. Neuromodulation. 2022; 25(7):1006-1014
  • Buters TP, Hameeteman PW, Jansen IME, et al. Intradermal lipopolysaccharide challenge as an acute in vivo inflammatory model in healthy volunteers. Br J Clin Pharmacol. 2022; 88(2):680-690.
  • Buters TP, Hameeteman PW, Jansen IME, et al. Clinical, Cellular, and Molecular Effects of Corticosteroids on the Response to Intradermal Lipopolysaccharide Administration in Healthy Volunteers. Clin Pharmacol Ther. 2022; 111(4):964-971.
  • Cohen AF, van Smeden J, Webb DJ. De-risking Clinical Trials: The BIAL Phase I Trial in Foresight. Clin Pharmacol Ther. 2022; 111(2):362-365.
  • Damman J, Mooyaart AL, Bosch TPPVD, et al. Lectin and alternative complement pathway activation in cutaneous manifestations of IgA-vasculitis: A new target for therapy? Mol Immunol. 2022; 143:114-121.
  • Dankers M, Nelissen-Vrancken HMJMG, Berger MY, et al. Recente en toekomstige behandelingen bij covid-19 [Current and future therapeutic options for COVID-19]. Ned Tijdschr Geneeskd. 2022; 166:D6675.
  • de Boer M, Gosselt HR, Jansen J, et al. Analysis and visualization of the course and burden over time of adverse drug reactions (ADRs) attributed to TNFα-inhibitors in patients with inflammatory rheumatic diseases (IRDs). Expert Opin Drug Saf. Published online 2022.
  • de Jong LM, Klomp SD, Treijtel N, et al. A systematic review on disease-drug-drug interactions with immunomodulating drugs: A critical appraisal of risk assessment and drug labelling. Br J Clin Pharmacol. 2022; 88(10):4387-4402.
  • de Las Heras B, Bouyoucef-Cherchalli D, Reeve L, et al. Healthy volunteers in first-in-human oncology drug development for small molecules. Br J Clin Pharmacol. 2022; 88(4):1773-1784.
  • Dijkstra F, O'Donnell P, Klaassen E, et al. Central nervous system effects of TAK-653, an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator in healthy volunteers. Transl Psychiatry. 2022; 12(1):408.
  • Dijkstra FM, van de Loo AJ, Abdulahad S, et al. The effects of intranasal esketamine on on-road driving performance in patients with major depressive disorder or persistent depressive disorder. J Psychopharmacol. 2022; 36(5):614-625.
  • Dijkstra FM, Zuiker RGJA, Siebenga PS, et al. Pharmacological profile of ALKS 7119, an investigational compound evaluated for the treatment of neuropsychiatric disorders, in healthy volunteers. Br J Clin Pharmacol. 2022; 88(6):2909-2925.
  • Donker EM, Brinkman DJ, van Rosse F, et al. Do we become better prescribers after graduation: A 1-year international follow-up study among junior doctors. Br J Clin Pharmacol. 2022; 88(12):5218-5226.
  • Donker EM, Pandit R, Poleij MCS, et al. The Dutch list of essential drugs for undergraduate medical education: A modified Delphi study. Br J Clin Pharmacol. Published online 2022.
  • Eveleens Maarse BC, Graff C, Kanters JK, et al. Effect of hydroxychloroquine on the cardiac ventricular repolarization: A randomized clinical trial. Br J Clin Pharmacol. 2022; 88(3):1054-1062.
  • Galema HA, Meijer RPJ, Lauwerends LJ, et al. Fluorescence-guided surgery in colorectal cancer; A review on clinical results and future perspectives. Eur J Surg Oncol. 2022; 48(4):810-821.
  • Grievink HW, Smit V, Huisman BW, et al. Cardiovascular risk factors: The effects of ageing and smoking on the immune system, an observational clinical study. Front Immunol. 2022; 13:968815.
  • Harrison SA, Manghi FP, Smith WB, et al. Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study. Nat Med. 2022; 28(7):1432-1438.
  • Hassing GJ, van Esdonk MJ, van Westen GJP, et al. Dose escalations in phase I studies: Feasibility of interpreting blinded pharmacodynamic data. Br J Clin Pharmacol. 2022; 88(12):5412-5419.
  • Heck J, Rath AK, Wons K, et al. Students' guide to documentation in clinical trials. Eur J Clin Pharmacol. 2022; 78(11):1861-1862.
  • Heuberger JAAC, Henning A, Cohen AF, et al. Dealing with doping. A plea for better science, governance and education. Br J Clin Pharmacol. 2022; 88(2):566-578.
  • Hijma H, Koopmans I, Klaassen E, et al. A crossover study evaluating the sex-dependent and sensitizing effects of sleep deprivation using a nociceptive test battery in healthy subjects. Br J Clin Pharmacol. 2023; 89(1):361-371.
  • Hijma HJ, van Brummelen EMJ, Siebenga PS, et al. A phase I, randomized, double-blind, placebo-controlled, single- and multiple dose escalation study evaluating the safety, pharmacokinetics and pharmacodynamics of VX-128, a highly selective Nav 1.8 inhibitor, in healthy adults. Clin Transl Sci. 2022; 15(4):981-993.
  • Huisman BW, Nené LEH, Linders FLL, et al. No effect of topical digoxin and furosemide for patients with actinic keratosis. J Eur Acad Dermatol Venereol. Published online 2022.
  • In 't Veld AE, Jansen MAA, Huisman BW, et al. Monitoring of Ex Vivo Cyclosporin a Activity in Healthy Volunteers Using T Cell Function Assays in Relation to Whole Blood and Cellular Pharmacokinetics. Pharmaceutics. 2022; 14(9):1958.
  • Kanhai KMS, Goulooze SC, van der Grond J, et al. Kinetics of myelin breakdown products: A labeling study in patients with progressive multiple sclerosis. Clin Transl Sci. 2022; 15(3):638-648.
  • Klomp SD, Meziyerh S, Vissers MFJM, et al. Increased Tacrolimus Exposure in Kidney Transplant Recipients With COVID-19: Inflammation-Driven Downregulation of Metabolism as a Potential Mechanism. Transpl Int. 2022; 35:10269.
  • Knijff JM, Houdijk ECAM, van der Kaay DCM, et al. Objective Home-Monitoring of Physical Activity, Cardiovascular Parameters, and Sleep in Pediatric Obesity. Digit Biomark. 2022; 6(1):19-29.
  • Kolkhir P, Laires PA, Salameh P, et al. The benefit of complete response to treatment in patients with chronic spontaneous urticaria - CURE results. J Allergy Clin Immunol Pract. Published online 2022.
  • Kruizinga MD, Essers E, Stuurman FE, et al. Clinical validation of digital biomarkers for paediatric patients with asthma and cystic fibrosis: potential for clinical trials and clinical care. Eur Respir J. 2022; 59(6):2100208.
  • Kruizinga MD, Zhuparris A, Dessing E, et al. Development and technical validation of a smartphone-based pediatric cough detection algorithm. Pediatr Pulmonol. 2022; 57(3):761-767.
  • Kruizinga MD, Zuiker RGJA, Bergmann KR, et al. Population pharmacokinetics of clonazepam in saliva and plasma: Steps towards noninvasive pharmacokinetic studies in vulnerable populations. Br J Clin Pharmacol. 2022; 88(5):2236-2245.
  • Kwee CM, van Gerven JM, Bongaerts FL, et al. Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration-effect relations using the IB-de-risk tool. J Psychopharmacol. 2022; 36(12):1299-1314.
  • Leijenaar JF, Ingala S, Sudre CH, et al. Decreased integrity of the monoaminergic tract is associated with a positive response to MPH in patients with vascular cognitive impairment - proof of principle study STREAM-VCI. Cereb Circ Cogn Behav. 2022; 3:100128.
  • Linders DGJ, Bijlstra OD, Fallert LC, et al. Cysteine Cathepsins in Breast Cancer: Promising Targets for Fluorescence-Guided Surgery. Mol Imaging Biol. Published online 2022.
  • Liu F, Aulin LBS, Guo T, et al. Modelling inflammatory biomarker dynamics in a human lipopolysaccharide (LPS) challenge study using delay differential equations. Br J Clin Pharmacol. 2022; 88(12):5420-5427.
  • Liu F, Aulin LBS, Kossen SSA, et al. A system pharmacology Boolean network model for the TLR4-mediated inflammatory response in early sepsis. J Pharmacokinet Pharmacodyn. 2022; 49(6):645-655.
  • Maleki G, Zhuparris A, Koopmans I, et al. Objective Monitoring of Facioscapulohumeral Dystrophy During Clinical Trials Using a Smartphone App and Wearables: Observational Study. JMIR Form Res. 2022; 6(9):e31775.
  • Marcec R, Dodig VM, Radanovic I, et al. Intravenous immunoglobulin (IVIg) therapy in hospitalised adult COVID-19 patients: A systematic review and meta-analysis. Rev Med Virol. 2022; 32(6):e2397.
  • Meijer RPJ, Faber RA, Bijlstra OD, et al. AVOID; a phase III, randomised controlled trial using indocyanine green for the prevention of anastomotic leakage in colorectal surgery. BMJ Open. 2022; 12(4):e051144.
  • Meijer RPJ, Neijenhuis LKA, Zeilstra AP, et al. Data-Driven Identification of Targets for Fluorescence-Guided Surgery in Non-Small Cell Lung Cancer. Mol Imaging Biol. Published online 2022.
  • Mieog JSD, Achterberg FB, Zlitni A, et al. Fundamentals and developments in fluorescence-guided cancer surgery. Nat Rev Clin Oncol. 2022; 19(1):9-22.
  • Moss LM, Algera MH, Dobbins R, et al. Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: A placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients. PLoS One. 2022; 17(1):e0256752.
  • Moss LM, Berends CL, van Brummelen EMJ, et al. First-in-human trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of STR-324, a dual enkephalinase inhibitor for pain management. Br J Clin Pharmacol. 2022; 88(1):103-114.
  • Muehlan C, Brooks S, Vaillant C, et al. Driving Performance after Bedtime Administration of Daridorexant, Assessed in a Sensitive Simulator. Clin Pharmacol Ther. 2022; 111(6):1334-1342.
  • Neijenhuis LKA, de Myunck LDAN, Bijlstra OD, et al. Near-Infrared Fluorescence Tumor-Targeted Imaging in Lung Cancer: A Systematic Review. Life (Basel). 2022; 12(3):446.
  • Niemeyer-van der Kolk T, Buters TP, Krouwels L, et al. Topical antimicrobial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild to moderate atopic dermatitis in a phase 2 randomized controlled trial. J Am Acad Dermatol. 2022; 86(4):854-862.
  • Olofsen E, Algera MH, Moss L, et al. Modeling buprenorphine reduction of fentanyl- induced respiratory depression. JCI Insight. 2022; 7(9):e156973.
  • Pagan L, Yfanti C, Rijneveld R, et al. Results of a randomized, placebo-controlled, first-in-human trial of topical CY-002 in patients with cutaneous warts. J Eur Acad Dermatol Venereol. 2022; 36(10):e773-e775.
  • Prins MLM, van der Plas JL, Vissers MFJM, et al. Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID-19: A phase 2a, open-label, single-dose escalation study. Br J Clin Pharmacol. Published online 2022.
  • Prins S, de Kam ML, Teunissen CE, et al. Inflammatory plasma biomarkers in subjects with preclinical Alzheimer's disease. Alzheimers Res Ther. 2022; 14(1):106.
  • Radanovic I, Klarenbeek NB, Rissmann R, et al. Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds. Front Oncol. 2022; 12:954806.
  • Roozen GVT, Prins MLM, van Binnendijk R, et al. Safety and Immunogenicity of Intradermal Fractional Dose Administration of the mRNA-1273 Vaccine: A Proof-of-Concept Study. Ann Intern Med. 2022; 175(12):1771-1774.
  • Ruijs TQ, Heuberger JAAC, de Goede AA, et al. Transcranial magnetic stimulation as biomarker of excitability in drug development: A randomized, double-blind, placebo-controlled, cross-over study. Br J Clin Pharmacol. 2022; 88(6):2926-2937.
  • Ruijs TQ, Koopmans IW, de Kam ML, et al. Muscle velocity recovery cycles as pharmacodynamic biomarker: Effects of mexiletine in a randomized double-blind placebo-controlled cross-over study. Clin Transl Sci. 2022; 15(12):2971-2981.
  • Ruijs TQ, Koopmans IW, de Kam ML, et al. Effects of Mexiletine and Lacosamide on Nerve Excitability in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study. Clin Pharmacol Ther. 2022; 112(5):1008-1019.
  • Saghari M, Gal P, Gilbert S, Yateman M, et al. OX40L Inhibition Suppresses KLH-driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof-of-Pharmacology for KY1005. Clin Pharmacol Ther. 2022; 111(5):1121-1132.
  • Saghari M, Gal P, Grievink HW, et al. Impact of oral administration of single strain Lactococcus lactiscremoris on immune responses to keyhole limpet hemocyanin immunization and gut microbiota: A randomized placebo-controlled trial in healthy volunteers. Front Immunol. 2022; 13:1009304.
  • Samb A, Kruizinga M, Tallahi Y, et al. Saliva as a sampling matrix for therapeutic drug monitoring of gentamicin in neonates: A prospective population pharmacokinetic and simulation study. Br J Clin Pharmacol. 2022; 88(4):1845-1855.
  • Schröder S, Heck J, Groh A, et al. White Blood Cell and Platelet Counts Are Not Suitable as Biomarkers in the Differential Diagnostics of Dementia. Brain Sci. 2022; 12(11):1424.
  • Stibbe JA, Hoogland P, Achterberg FB, et al. Highlighting the Undetectable - Fluorescence Molecular Imaging in Gastrointestinal Endoscopy. Mol Imaging Biol. Published online 2022.
  • Stuijt DG, Exadaktylos V, Bins AD, et al. Potential Role of Smartphone-Based Passive Sensing in Remote Monitoring of Patients With Cancer. JCO Clin Cancer Inform. 2022; 6:e2200079.
  • Te Beek ET, Burggraaf J, Teunissen JJM, et al. Clinical Pharmacology of Radiotheranostics in Oncology. Clin Pharmacol Ther. Published online 2022.
  • Thiboutot DM, Craft N, Rissmann R, et al. Anti-IL-17A blockade did not significantly reduce inflammatory lesions in a placebo-controlled pilot study in adult patients with moderate to severe acne. J Dermatolog Treat. Published online 2022.
  • Thijssen E, den Heijer JM, Puibert D, et al. A Randomized Trial Assessing the Safety, Pharmacokinetics, and Efficacy During Morning Off of AZ-009. Mov Disord. 2022; 37(4):790-798.
  • Thijssen E, den Heijer JM, Puibert D, et al. Safety and pharmacokinetics of multiple dosing with inhalable apomorphine (AZ-009), and its efficacy in a randomized crossover study in Parkinson's disease patients. Parkinsonism Relat Disord. 2022; 97:84-90.
  • Thijssen E, Makai-Bölöni S, van Brummelen EMJ, et al. A Placebo-Controlled Study to Assess the Sensitivity of Finger Tapping to Medication Effects in Parkinson's Disease. Mov Disord Clin Pract. 2022; 9(8):1074-1084.
  • van den Berg B, Hijma HJ, Koopmans I, et al. Simultaneous measurement of intra-epidermal electric detection thresholds and evoked potentials for observation of nociceptive processing following sleep deprivation. Exp Brain Res. 2022; 240(2):631-649.
  • van der Wall HEC, Hassing GJ, Doll RJ, et al. Cardiac age detected by machine learning applied to the surface ECG of healthy subjects: Creation of a benchmark. J Electrocardiol. 2022; 72:49-55.
  • van Diemen MPJ, Ziagkos D, Kruizinga MD, et al. Mitochondrial function, grip strength, and activity are related to recovery of mobility after a total knee arthroplasty. Clin Transl Sci. Published online 2022.
  • van Schie P, van der Lelij TJN, Gerritsen M, et al. Intra-operative assessment of the vascularisation of a cross section of the meniscus using near-infrared fluorescence imaging. Knee Surg Sports Traumatol Arthrosc. 2022; 30(5):1629-1638.
  • Vissers MFJM, Heuberger JAAC, Groeneveld GJ, et al. Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients. Clin Transl Sci. 2022; 15(8):2010-2023.
  • Vrouwe JPM, Hennus PML, Hamdy NAT, et al. Risk of osteoporosis in testicular germ cell tumour survivors: A systematic review of the literature. BJUI Compass. 2022; 4(1):24-43.
  • Vrouwe JPM, Meulenberg JJM, Klarenbeek NB, et al. Administration of an adeno-associated viral vector expressing interferon-β in patients with inflammatory hand arthritis, results of a phase I/II study. Osteoarthritis Cartilage. 2022; 30(1):52-60.
  • Wind S, Jansen MAA, Rijsbergen M, et al. Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial. Cancers (Basel). 2022; 14(6):1510.
  • Yu HJ, Thijssen E, van Brummelen EMJ, et al. A Randomized First-in-Human Study With UB-312, a UBITh® α-Synuclein Peptide Vaccine. Mov Disord. 2022; 37(7):1416-1424. 

Interested in learning more?

Back to homepage